These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 33464318)

  • 1. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
    Zeng X; Wan X; Peng L; Peng Y; Ma F; Liu Q; Tan C
    BMJ Open; 2019 Dec; 9(12):e031019. PubMed ID: 31831534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
    Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
    JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
    Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
    Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
    Hu X; Hay JW
    Lung Cancer; 2018 Sep; 123():166-171. PubMed ID: 30089590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
    Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
    JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen F; Huang P; Wu Q; Yang Y; Zhou K; Zhang M; Li Q
    Cancer Med; 2024 Aug; 13(16):e70094. PubMed ID: 39149756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
    Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
    Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
    Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
    J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.